Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Valerates”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 217 records · Page 12Linked to original sources
PubMed2003

Efficacy of betamethasone valerate 0.1% thermophobic foam in seborrhoeic dermatitis of the scalp: an open-label, multicentre, prospective trial on 180 patients.

BACKGROUND: Seborrhoeic dermatitis (SD) is a common chronic inflammatory disease of the skin. Topical steroid creams and/or antifungal agents are commonly used in SD, but no resolutive therapies have been available up to now. Furthermore, little data have been available regarding clinical outcomes after cessation of topical treatments. A new formulation of betamethasone valerate 0.1% in a thermophobic, low-residue, foam vehicle (Bettamousse) (BVM) has become available for the topical treatment of scalp dermatoses. No data have been published hitherto regarding efficacy, safety and patient acceptability of this new formulation for the treatment of SD of the scalp. STUDY AIM: To assess in an open-label, prospective, multicentre trial, the efficacy, safety and patient acceptability of BVM, as compared to baseline, in SD subjects with scalp involvement. PATIENTS AND METHODS: A total of 180 patients with moderate-to-severe SD of the scalp were enrolled in the trial. Efficacy was evaluated by analysing SD lesions for erythema, scaling and itching using a five-point grading score (0 = lesion completely cured; 1 = mild; 2 = moderate; 3 = severe and 4 = very severe lesion). The clinical global (sum) score was obtained adding the score of each item. Efficacy and safety were assessed at baseline, after 4 weeks of active treatment, followed by an 8-week follow-up period with no treatment. RESULTS: In comparison with baseline, BVM significantly improved SD lesions. The sum score was reduced from 6.3 +/- 1.8 to 1.4 +/- 1.4 at the end of the active treatment period, (p < 0.0001) and to 1.7 +/- 1.8 at the end of the 8-week follow-up period (p < 0.0001). After active treatment, 93% of the patients had a sum score of </=3). At the end of 8-week of follow-up, 88% of patients maintained a sum score </=3. In addition, 85% of patients considered BVM foam to be a better topical formulation both in terms of efficacy and acceptability compared with previous treatments used. CONCLUSION: BVM is an effective and well-tolerated topical treatment of scalp SD. Its clinical effect is also maintained after a 2-month wash-out period.

Anti-Inflammatory Agents↗
PubMed2007

An efficient new formulation of fusidic acid and betamethasone 17-valerate (fucicort lipid cream) for treatment of clinically infected atopic dermatitis.

To relieve the dryness of atopic dermatitis skin, a lipid formulation of fusidic acid and betamethasone 17-valerate (Fucicort Lipid cream) was developed as an additional treatment option to the established Fucicort cream. The two formulations were compared in patients with clinically infected atopic dermatitis. A total of 629 patients were randomized to twice daily double-blind treatment for 2 weeks with either Fucicort Lipid cream, Fucicort cream, or the new lipid cream vehicle. Clinical assessment was based on a Total Severity Score of the eczematous lesions. Bacteriological samples were taken at inclusion and at subsequent visit(s) if clinically infected lesions persisted. At the end of treatment, the mean reduction in Total Severity score was 82.9% in the lipid cream group, 82.7% in the cream group, and 33.0% in the vehicle group. The percentage of patients with a successful bacteriological response was 89.7%, 89.6% and 25.0%, respectively. Thus, the clinical and anti-bacterial effect of the lipid cream was found to be similar to that of the established cream formulation, and significantly better than that of the vehicle. The new lipid formulation, therefore, offers an efficient, safe and well-tolerated alternative for the short-term treatment of clinically infected atopic dermatitis.

Administration, Topical↗
PubMed2002

Therapeutic effect of topical application of linoleic acid and lincomycin in combination with betamethasone valerate in melasma patients.

Melasma is an acquired symmetric hypermelanosis characterized by irregular light-to gray-brown macules and patches on sun-exposed areas. Many therapeutic agents are available but are unsatisfactory. Recently, it has been demonstrated that lincomycin (LM) and linoleic acid (LA) can inhibit melanogenesis in vitro. Our purpose was to investigate the clinical efficacy of topical application of LM and LA in combination with betamethasone valerate (BV) in melasma patients. Forty-seven Korean female adults with clinically diagnosed melasma were enrolled in a 6-week, double-blind, randomized clinical trial. Patients were treated with one application of the vehicle (group A), 2% LM mixed with 0.05% BV (group B), or 2% LM mixed with 0.05% BV and 2% LA (group C) on the face every night. Determination of efficacy was based on the Melasma Area and Severity Index (MASI) score and objective assessment (no effect, mild, moderate, or excellent) at intervals of 2 weeks until the end of the study at 6 weeks. After 6 weeks, in comparison with the pre-treatment MASI score, the average MASI score of group C decreased to 68.9%, compared with 98% in group A (p<0.05) and 85.4% in group B. There was no statistically significant difference between group A and group B. Seven patients (43.7%) in group C revealed more than moderate improvement in objective assessment, compared with none in group A and two patients (12.5%) in group B. There were no significant side effects. Topical application of linoleic acid is considered to be effective in the treatment of melasma patients.

Administration, Topical↗
PubMed1975

Double-blind comparison of halcinonide and betamethasone valerate. Use with occlusive dressings in psoriasis treatment.

In a double-blind, paired-comparison study of the effectiveness of corticosteroid creams used under occlusion for the treatment of moderate to severe psoriasis, a new drug, halcinonide cream, was superior to betamethasone valerate cream, a steroid widely and effectively used for the treatment of psoriasis. This superiority was demonstrated in patients after both one and two weeks of treatment.

Administration, Topical↗
PubMed2002

Using oral tetracycline and topical betamethasone valerate to treat acrodermatitis continua of hallopeau.

Acrodermatitis continua of Hallopeau (ACH) is a rare type of localized pustular psoriasis. We report the case of a 65-year-old alcoholic woman who had severe inflammatory ACH for 10 years. Initial therapy with sulfasalazine was unsuccessful. The patient was then treated with oral tetracycline and topical betamethasone valerate with occlusive dressing. Her condition improved dramatically after one week.

Acrodermatitis↗
PubMed2005

An open label study of clobetasol propionate 0.05% and betamethasone valerate 0.12% foams in the treatment of mild to moderate acne keloidalis.

Acne keloidalis (AK) is a disease affecting primarily African American men. Topical steroids are a widely accepted treatment of AK; however, no studies have been published investigating their effectiveness. The purpose of this open-label study was to assess the efficacy and tolerability of clobetasol propionate 0.05% and betamethasone valerate 0.12% foams in the treatment of AK in 20 African American patients. These patients were treated for 8 to 12 weeks using a pulsed-dose regimen. We found topical clobetasol propionate foam to be effective in improving AK, and our patients found the foam vehicle to be cosmetically acceptable.

Acne Keloid↗
PubMed1990

Therapeutic response to a dermatologic patch and betamethasone valerate 0.1 percent cream in the management of chronic plaques in psoriasis.

The efficacy of a hydrocolloid dermatologic patch (Actiderm) in conjunction with topical beta-methasone valerate 0.1 percent cream was studied in outpatients with chronic plaque-type psoriasis treated for three weeks, and observed for an additional two weeks after therapy. A significant degree (p less than 0.05) of lesion resolution occurred at the site treated with the dermatologic patch plus steroid cream, whereas sites treated with either agent alone showed mild but insignificant change. It was concluded that the patch was a highly effective adjunct in the treatment of chronic plaques of psoriasis.

Administration, Topical↗
PubMed1977

Betamethasone valerate inhalation and exercise-induced asthma in adults.

The effect of regular inhalation of betamethasone valerate (800 microgram daily) on exercise-induced asthma has been studied in 18 adult patients. The active aerosol was compared with placebo in a double-blind cross-over study, each inhaler being used for four weeks. Exercise tests after each period of treatment were performed using a cycle ergometer, care being taken to match the oxygen uptake during exercise each time a patient was tested. Twelve patients experienced less exercise-induced fall in peak expiratory flow rate after the corticosteroid inhaler, while six did not. This effect appeared to be independent of any alteration in base-line lung function, suggesting that it was due primarily to diminution of bronchial hyperreactivity. It is suggested that this change may have been due to interference with the synthesis or release of mediator substances from mast cells.

Adolescent↗
PubMed1985

Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo.

Five corticosteroid ointments and placebo were compared in 17 volunteers with regard to their influence on normal skin under occlusive conditions. Each volunteer had six simultaneous applications on the forearms and six on the back. The trial was double-blind and lasted 4 weeks. The ointments were placed in randomized order. The treatments were 0.1 and 0.03% domoprednate, 0.1% hydrocortisone butyrate, 0.1% betamethasone valerate, 0.05% clobetasole propionate and placebo. Skin thickness was measured on days 0, 7, 14, 21 and 28, transepidermal water loss on days 0, 14 and 28, while blood flow and telangiectasias were evaluated only on day 28 at termination of the trial. The skin thickness became significantly reduced on all corticosteroids, but not on placebo; 0.03% domoprednate, however, tended to have an intermediate position between placebo and the other ointments. The transepidermal water loss did not change. Rating of telangiectasia under stereomicroscope showed a significantly lower score after 0.03% domoprednate and placebo as compared to the other ointments. Assessment of telangiectasia by laser-Doppler flowmetry showed a similar tendency. It is concluded that 0.1% domoprednate is comparable to other topical corticosteroids with respect to atrophogeneity and formation of telangiectasia, but the 0.03% concentration seems to result in fewer side effects.

Administration, Topical↗
PubMed1985

The treatment of psoriasis with 0.1% domoprednate (a D-homocorticosteroid) and 0.1% betamethasone valerate ointment. A double-blind, randomized trial.

In 85 patients with psoriasis vulgaris the efficacy and tolerance of domoprednate and betamethasone valerate were studied in a double-blind, randomized trial lasting 4 weeks. Complete or satisfactory remission was obtained in 36% in the domoprednate group and in 53% in the betamethasone group. This difference is not statistically significant (p greater than 0.10). 3 patients on each treatment experienced some local irritation. No laboratory abnormalities were found during the study.

Adolescent↗
PubMedDate not supplied

Synthesis of alpha-[7-methyl-9-methoxy-5-oxo-furo-[3,2-g] [1]-benzopyranoxy-4]-butyric and valeric acids and their aminoesters.

In the reaction of 4-desmethylkhelline with ethyl alpha-bromobutyrate or alpha-bromovalerate we obtained alpha-[7-methyl-9-methoxy-5-oxo-furo[3,2-g] [1] benzopyranoxy-4]-butyric 2 and valeric 3 acids and later their dialkylaminoethylesters as hydrochlorides (2b--2, 3b--3e). Compounds 2c, 2e, 2f (Table 1) and 3e (Table 2) show a weak hypotensic activity. Moreover compound 2f possesses an antriarrhythmic activity.

Aminobutyrates↗
PubMed1983

Effect of betamethasone valerate on the normal human facial skin flora.

Eighteen volunteers were randomly divided into two groups and allocated either an active corticosteroid preparation (Betamethasone valerate) or the basal formulation only (placebo). The cream was applied to the face twice daily for one month. The treated area was sampled by the scrub-wash method immediately before treatment began and after 2 and 4 weeks, and microorganisms were enumerated and identified. Application of either cream produced a very slight increase (less than or equal to 0.5 log cycle) in the skin flora during the first 2 weeks of treatment. There were no significant differences in the changes occurring between volunteers treated with placebo and those on the steroid formulation. The results are discussed in relation to theories of pathogenesis of perioral dermatitis and steroid acne.

Betamethasone↗
PubMed1976

[The use of difluocortolone valerate in various dermatoses].

Diflucortolone valerate was clinically investigated as a fatty ointment in 30 dermatological patients. Although this form of application is a special presentation for the treatment of very dry dermatoses, patients with not so dry and weeping dermatoses were also treated in this trial, the object being to include the role played by the vehicle in the results of therapy. Very good to good results were achieved in 80% of the cases treated, while the result was observed to be poor in only 10% of the cases. This latter percentage is comprised for the greater part of patients who had previously been treated with other corticoids and of patients with weeping dermatoses.

Administration, Topical↗
PubMed1976

[Difluocortolone valerate in dermatology].

The investigational preparation Nerisona Cream (diflucortolone valerate 0.1%, investigational no. SH K 183 MB) was used in 47 patients with various inflammatory or pruriginous dermatoses. Either very good or good results were achieved in 89.3% of the cases. Nearly all the patients thought highly of the cosmetic properties of the preparation. No side effects were observed.

Administration, Topical↗
PubMed1976

[Difluocortolone valerate: a new corticoid for topical use].

The clinical efficacy of diflucortolone valerate as a fatty ointment was investigated in 65 patients with very dry dermatoses. The results were very positive, being excellent in atopic eczema, neurodermatitis and atopic cheilitis. No side effects were observed.

Administration, Topical↗
PubMed1976

[Difluocortolone valerate for topical use in dermatology].

59 patients with various skin disorders - most of them in the acute stage - were treated in this trial. The topical investigational preparation was a cream containing 0.1% diflucortolone valerate. The results confirmed that the preparation has a quick-acting and effective antipruritic and antiphlogistic action. The results achieved were good or very good in 91.52% of cases and moderate in 8.47%. No side effects were observed.

Administration, Topical↗